Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 1,301 Shares

Posted by Francis Steltz on Aug 7th, 2026

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) insider Tobin Juvenal sold 1,301 shares of the firm’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $38.39, for a total transaction of $49,945.39. Following the completion of the transaction, the insider directly owned 77,694 shares in the company, valued at $2,982,672.66. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Up 0.2%

Shares of NASDAQ CSTL opened at $30.47 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. The company has a 50-day moving average price of $23.55 and a 200-day moving average price of $26.16. The stock has a market capitalization of $930.86 million, a P/E ratio of -46.17 and a beta of 0.98. Castle Biosciences, Inc. has a 1 year low of $17.72 and a 1 year high of $44.28.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.34. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The company had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. On average, equities research analysts forecast that Castle Biosciences, Inc. will post -1.29 EPS for the current fiscal year.

Castle Biosciences News Roundup

Here are the key news stories impacting Castle Biosciences this week:

Positive Sentiment: BTIG raised its price target to $44 from $40 and maintained a “buy” rating. The higher target reflects confidence in Castle Biosciences’ molecular-diagnostics growth outlook and suggests meaningful upside from recent trading levels. BTIG raises Castle Biosciences price target
Positive Sentiment: Castle Biosciences’ latest quarterly results significantly exceeded expectations. Revenue reached $99.86 million versus the $86.23 million consensus estimate, while the per-share loss was $0.07 compared with the expected $0.41 loss. The company remains unprofitable, but the revenue growth and narrower loss reinforce the improving operating outlook.
Neutral Sentiment: Institutional investors and hedge funds continue to hold approximately 92.6% of Castle Biosciences’ outstanding shares. Recent position increases by firms including AQR Capital Management, Amundi and Legal & General may provide some institutional support, although these ownership changes are not necessarily a near-term catalyst.
Negative Sentiment: Several insiders reported sizable stock sales. Derek J. Maetzold sold 39,016 shares for roughly $1.21 million in transactions on August 4–5, while COO Kristen Oelschlager sold 8,586 shares for about $256,000. Tobin W. Juvenal also disclosed a 1,730-share sale worth approximately $49,000. The sales reduce insider ownership and could weigh on sentiment after the stock’s recent advance, although the transactions were executed under pre-arranged Rule 10b5-1 plans, making them a less definitive bearish signal. Castle Biosciences insider sales filing

Institutional Trading of Castle Biosciences

A number of hedge funds have recently bought and sold shares of the business. Truist Financial Corp increased its stake in Castle Biosciences by 1.1% in the 4th quarter. Truist Financial Corp now owns 23,628 shares of the company’s stock worth $919,000 after acquiring an additional 257 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Castle Biosciences by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after buying an additional 297 shares in the last quarter. CWM LLC raised its stake in shares of Castle Biosciences by 20.5% during the fourth quarter. CWM LLC now owns 2,302 shares of the company’s stock worth $90,000 after acquiring an additional 391 shares in the last quarter. HRT Financial LP raised its position in Castle Biosciences by 0.9% in the 4th quarter. HRT Financial LP now owns 47,654 shares of the company’s stock worth $1,853,000 after purchasing an additional 415 shares during the period. Finally, Assetmark Inc. increased its holdings in shares of Castle Biosciences by 9.3% in the first quarter. Assetmark Inc. now owns 5,779 shares of the company’s stock worth $142,000 after buying an additional 492 shares during the period. 92.60% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

CSTL has been the subject of several recent research reports. Weiss Ratings upgraded Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st. Zacks Research downgraded shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. KeyCorp set a $35.00 target price on shares of Castle Biosciences in a research note on Friday, May 29th. Roth Capital began coverage on shares of Castle Biosciences in a report on Wednesday, June 24th. They issued a “buy” rating and a $40.00 target price for the company. Finally, Canaccord Genuity Group dropped their price target on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

Read Our Latest Report on CSTL

About Castle Biosciences

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.